News

¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for mCRPC

View more

Nov 15, 2022

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

View more

Nov 15, 2022

PET/MRI shows promise for imaging infection, inflammation

View more

Nov 14, 2022

PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients

View more

Nov 14, 2022

Targeting refractory prostate cancer: A novel radiopharmaceutical hits the bullseye

View more

Nov 11, 2022

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

View more

Nov 10, 2022